menu
    • menu

    Company profile for Orion Corporation

    Fermion-PSE
    News
    Orion Announces Improved Financial Outlook For Coming Year

    15 Jan 2025

    // PRESS RELEASE

    Orion Committee Prepares Proposals For Annual Meeting Agenda

    15 Jan 2025

    // PRESS RELEASE

    Orion’s partner Bayer in China for 3rd indication of darolutamide

    08 Jan 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Fermion

    Contact Supplier

    Website

    PharmaVenue

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.youtube.com/embed/NUY-WJrSlVU

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Related CompaniesRelated Companies

    About

    Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's customers are mainly healthcare service providers and professionals such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics, etc.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Orion CorporationFinland Flag
    Country
    Country
    Finland
    Address
    Address
    Head officeOrion CorporationOrionintie 1A, FI-02200 Espoo, FinlandP.O.Box 65, ...
    Telephone
    Telephone
    +358 10 4261
    Client Email
    Email
    fermionSales@fermion.fi
    Client Website
    Website
    https://www.orion.fi/en/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/orion-corporation/
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    NEWS #PharmaBuzz

    read-more
    read-more
    Orion Announces Improved Financial Outlook For Coming Year
    Orion Announces Improved Financial Outlook For Coming Year

    15 Jan 2025

    // PRESS RELEASE

    https://www.orion.fi/en/newsroom/all-news/releases/stock-releases/2024/inside-information-orion-upgrades-full-year-outlook-for-2024/

    PRESS RELEASE
    15 Jan 2025
    Share Share
    Orion Committee Prepares Proposals For Annual Meeting Agenda
    Orion Committee Prepares Proposals For Annual Meeting Agenda

    15 Jan 2025

    // PRESS RELEASE

    https://www.orion.fi/en/newsroom/all-news/releases/stock-releases/2025/recommendation-by-the-orion-nomination-committee-on-the-proposals-to-be-submitted-to-the-2025-annual-general-meeting/

    PRESS RELEASE
    15 Jan 2025
    Share Share
    Orion’s partner Bayer in China for 3rd indication of darolutamide
    Orion’s partner Bayer in China for 3rd indication of darolutamide

    08 Jan 2025

    // PRESS RELEASE

    https://www.orion.fi/en/newsroom/all-news/releases/press-releases/2025/orions-collaboration-partner-bayer-submits-application-in-china-for-third-indication-of-darolutamide/

    PRESS RELEASE
    08 Jan 2025
    Share Share
    Orion and Marinus terminate agreement for ganaxolone in Europe
    Orion and Marinus terminate agreement for ganaxolone in Europe

    02 Jan 2025

    // PRESS RELEASE

    https://www.orion.fi/en/newsroom/all-news/releases/press-releases/2024/orion-and-marinus-terminate-agreement-for-ganaxolone-in-europe/

    PRESS RELEASE
    02 Jan 2025
    Share Share
    Orion and Marinus terminate agreement for ganaxolone in Europe
    Orion and Marinus terminate agreement for ganaxolone in Europe

    30 Dec 2024

    // #N/A

    https://www.orion.fi/en/newsroom/all-news/releases/press-releases/2024/orion-and-marinus-terminate-agreement-for-ganaxolone-in-europe/

    #N/A
    30 Dec 2024
    Share Share
    Abilita and Orion Announce Research Collab to Next-Gen Antibody
    Abilita and Orion Announce Research Collab to Next-Gen Antibody

    19 Dec 2024

    // PRESS RELEASE

    https://www.orion.fi/en/newsroom/all-news/releases/press-releases/2024/orion-and-abilita-therapeutics-announce-research-collaboration-and-option-to-license-agreement-to-develop-innovative-antibody-therapeutics/

    PRESS RELEASE
    19 Dec 2024
    Share Share

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search